Romark Laboratories LC:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Romark Laboratories LC - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7599
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:18
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Romark Laboratories LC (Romark Laboratories) is a pharmaceutical company that discovers, develops and commercializes small molecules for the treatment of infectious diseases and cancers. The company develops Nitazoxanide, an oral suspension and tablets used for the treatment of intestinal parasitic infections caused by the intestinal protozoa cryptosporidium parvum, giardia intestinalis, entamoeba hystolitica, blastocystis hominis and balantidium coli. Its pipeline products include NT-300, RM-5061, RM-5038 and RM-5064. Romark Laboratories’ pipeline products are used for the treatment of various indications such as anti-infective, antiviral, influenza and RSV. The company operates through its manufacturing facility located in Belgium and Puerto Rico. Romark Laboratories is headquartered in Tampa, Florida, the US.

Romark Laboratories LC – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Romark Laboratories LC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Romark Laboratories LC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Romark Laboratories LC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Romark Laboratories LC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Romark Laboratories LC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Romark Laboratories LC, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Romark Labs Raises USD2 Million in Venture Financing 10
Partnerships 11
Clinigen Enters into Distribution Agreement with Romark Labs 11
Licensing Agreements 12
Romark Labs Enters Into Licensing Agreement With Lupin For Alinia 12
Equity Offering 13
Romark Labs Raises USD10.8 Million in Private Placement of Preferred Shares 13
Romark Labs Raises USD15 Million in Private Placement of Preferred Shares 14
Romark Laboratories LC – Key Competitors 15
Romark Laboratories LC – Key Employees 16
Romark Laboratories LC – Locations And Subsidiaries 17
Head Office 17
Appendix 18
Methodology 18
About GlobalData 18
Contact Us 18
Disclaimer 18

List of Tables
Romark Laboratories LC, Pharmaceuticals & Healthcare, Key Facts 2
Romark Laboratories LC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Romark Laboratories LC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Romark Laboratories LC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Romark Laboratories LC, Deals By Therapy Area, 2012 to YTD 2018 8
Romark Laboratories LC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Romark Labs Raises USD2 Million in Venture Financing 10
Clinigen Enters into Distribution Agreement with Romark Labs 11
Romark Labs Enters Into Licensing Agreement With Lupin For Alinia 12
Romark Labs Raises USD10.8 Million in Private Placement of Preferred Shares 13
Romark Labs Raises USD15 Million in Private Placement of Preferred Shares 14
Romark Laboratories LC, Key Competitors 15
Romark Laboratories LC, Key Employees 16

List of Figures
Romark Laboratories LC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Romark Laboratories LC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Romark Laboratories LC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Romark Laboratories LC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Romark Laboratories LC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Romark Laboratories LC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Romark Laboratories LC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Romark Laboratories LC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Romark Laboratories LC:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Aspen Pharmacare Holdings Ltd (APN):企業の財務・戦略的SWOT分析
    Aspen Pharmacare Holdings Ltd (APN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Tribune Media Company:戦略・SWOT・企業財務分析
    Tribune Media Company - Strategy, SWOT and Corporate Finance Report Summary Tribune Media Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Athena Investments AS (ATHENA):電力:M&Aディール及び事業提携情報
    Summary Athena Investments AS(Athena), Previously known as Greentech Energy System A/S is an energy company which operates renewable energy plants. It generates electricity from wind and solar sources. Through long-term power purchase agreements, the company sells electricity. Athena expands its ass …
  • IMPSA SA:企業の戦略的SWOT分析
    IMPSA SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Thi …
  • Standard Alliance Insurance Plc:企業の戦略・SWOT・財務情報
    Standard Alliance Insurance Plc - Strategy, SWOT and Corporate Finance Report Summary Standard Alliance Insurance Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Enphase Energy, Inc. (ENPH):電力:M&Aディール及び事業提携情報
    Summary Enphase Energy, Inc. (EEI), formerly PVI Solutions, Inc., is an energy management solutions provider that designs, develops, manufactures and sells microinverter system. Its semiconductor-based microinverter system converts direct current (DC) electricity to alternating current (AC) electric …
  • Geron Corp (GERN)-製薬・医療分野:企業M&A・提携分析
    Summary Geron Corp (Geron) is a clinical stage biopharmaceutical company, which develops a telomerase inhibitor as a potential treatment for cancer. The company is evaluating its flagship product candidate Imetelstat in two clinical trials: IMbark and IMerge in partnership with Janssen Biotech, Inc. …
  • Circle Pharma Inc-製薬・医療分野:企業M&A・提携分析
    Summary Circle Pharma Inc. (Circle Pharma) is a drug development company that strives to develop cell permeable macrocyclic peptide therapies by combining computational design and synthetic chemistry. Its technology platform is applicable in a wide range of disease conditions such as fibrosis, infla …
  • FalconStor Software Inc (FALC):企業の財務・戦略的SWOT分析
    Summary FalconStor Software Inc (FalconStor) is a technology company that offers data protection and storage virtualization solutions. The company offers freestor, continuous data protector, and network storage server. It offers freestor, which supports to manage data to deliver real-time informatio …
  • Ergon, Inc.:石油・ガス:M&Aディール及び事業提携情報
    Summary Ergon Inc (Ergon) is an integrated energy company that carries out the exploration and production of crude oil and natural gas, processing, transportation and terminaling of crude oil, storage, marketing and distribution of specialty petroleum products. The company also manufactures and mark …
  • Kmart Corporation:企業の戦略的SWOT分析
    Kmart Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Electricity Generating Public Co Ltd (EGCO)-エネルギー分野:企業M&A・提携分析
    Summary Electricity Generating Public Co Ltd (EGCO), a subsidiary of Electricity Generating Authority of Thailand (EGAT), is an energy utility. It produces electricity from natural gas, coal, biomass, waste, hydro, solar, wind, and geothermal sources. Through interests in independent power producer …
  • Sosei Group Corp (4565):製薬・医療:M&Aディール及び事業提携情報
    Summary Sosei Group Corp (Sosei) is a biopharmaceutical company that develops and commercializes drugs. The company’s pipeline products include NorLevo, NVA237, QVA149 and SO-1105. Its NorLevo product is an oral emergency contraceptive; and SO-1105 is an antifungal agent, administered as a muco-adhe …
  • Electricity Generating Public Co Ltd:企業の発電所・SWOT分析2018
    Electricity Generating Public Co Ltd - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information …
  • Powerco Ltd:企業の戦略的SWOT分析
    Powerco Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • ITOCHU Corporation:企業の戦略・SWOT・財務情報
    ITOCHU Corporation - Strategy, SWOT and Corporate Finance Report Summary ITOCHU Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Nexstim Plc (NXTMH)-医療機器分野:企業M&A・提携分析
    Summary Nexstim Plc (Nexstim) is a medical technology company, which focuses on navigated brain stimulation (NBS) to improve rehabilitation in stroke patients non-invasively . Its NBS system, which is FDA cleared and CE-marked, applies navigated transcranial magnetic stimulation (nTMS) device for pr …
  • Mizuho Trust & Banking Co Ltd:企業の戦略・SWOT・財務分析
    Mizuho Trust & Banking Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Mizuho Trust & Banking Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Meyer Burger Technology AG (MBTN)-エネルギー分野:企業M&A・提携分析
    Summary Meyer Burger Technology AG (Meyer Burger) is a technology company that provides technology, systems, machinery and processes for cutting and handling crystalline and other high-grade materials. It supplies ultra-thin wafers made from silicon, sapphire or other crystals for the manufacture of …
  • ReShape Lifesciences Inc (RSLS):医療機器:M&Aディール及び事業提携情報
    Summary ReShape Lifesciences Inc (ReShape), formerly known as EnteroMedics Inc is a medical device company that develops minimally invasive medical devices to treat obesity and metabolic diseases. The company develops vBloc, a therapy used in the treatment of gastrointestinal and neurometabolic dise …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆